TWI839729B - 與Fc受體結合改變的Fc突變體 - Google Patents

與Fc受體結合改變的Fc突變體 Download PDF

Info

Publication number
TWI839729B
TWI839729B TW111117182A TW111117182A TWI839729B TW I839729 B TWI839729 B TW I839729B TW 111117182 A TW111117182 A TW 111117182A TW 111117182 A TW111117182 A TW 111117182A TW I839729 B TWI839729 B TW I839729B
Authority
TW
Taiwan
Prior art keywords
seq
sequence
index
amino acids
light chain
Prior art date
Application number
TW111117182A
Other languages
English (en)
Chinese (zh)
Other versions
TW202246313A (zh
Inventor
付鳳根
周帥祥
吳志海
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202246313A publication Critical patent/TW202246313A/zh
Application granted granted Critical
Publication of TWI839729B publication Critical patent/TWI839729B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111117182A 2021-05-07 2022-05-06 與Fc受體結合改變的Fc突變體 TWI839729B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN202110495363.7 2021-05-07
CN202210436873 2022-04-25
CN202210436873.1 2022-04-25

Publications (2)

Publication Number Publication Date
TW202246313A TW202246313A (zh) 2022-12-01
TWI839729B true TWI839729B (zh) 2024-04-21

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111117182A TWI839729B (zh) 2021-05-07 2022-05-06 與Fc受體結合改變的Fc突變體

Country Status (8)

Country Link
US (1) US20240228579A1 (https=)
EP (1) EP4335868A4 (https=)
JP (1) JP2024516320A (https=)
CN (1) CN117295760A (https=)
AU (1) AU2022269145A1 (https=)
CA (1) CA3218187A1 (https=)
TW (1) TWI839729B (https=)
WO (1) WO2022233320A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121712795A (zh) * 2023-08-30 2026-03-20 安斯泰来制药株式会社 Fc区改造体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
CN108713027A (zh) * 2015-12-17 2018-10-26 詹森生物科技公司 特异性结合hla-dr的抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
RU2639287C2 (ru) * 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2018027204A1 (en) * 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
CN108713027A (zh) * 2015-12-17 2018-10-26 詹森生物科技公司 特异性结合hla-dr的抗体及其用途

Also Published As

Publication number Publication date
JP2024516320A (ja) 2024-04-12
EP4335868A1 (en) 2024-03-13
EP4335868A4 (en) 2025-08-13
US20240228579A1 (en) 2024-07-11
CN117295760A (zh) 2023-12-26
WO2022233320A1 (zh) 2022-11-10
TW202246313A (zh) 2022-12-01
CA3218187A1 (en) 2022-11-10
AU2022269145A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
KR102332303B1 (ko) 감소되거나 침묵화된 효과기 기능을 갖는 이종다량체
CN113817049B (zh) 修饰的Fc片段在免疫疗法中的应用
JP2026021377A (ja) ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
CN111601821B (zh) 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
JP2020508666A (ja) 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤
JP2025098167A (ja) Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
TWI839729B (zh) 與Fc受體結合改變的Fc突變體
JP2025517120A (ja) アルブミン結合ポリペプチド及びその使用
KR20240046239A (ko) 항-vegfr1 항체 및 이들의 용도
CN115175736A (zh) 杂交抗体
CN116783220A (zh) 抗bcma抗体及其制备方法和应用
US20250340613A1 (en) Bispecific antibody comprising a heterodimer based on mhc proteins
CN120590537A (zh) 靶向tigit的双特异性抗体
WO2011106272A1 (en) Novel binding assays useful in identifying antibodies with altered half-lives
CN115322255B (zh) 一种优化的Fc变体及其应用
TW202409086A (zh) FcRn-結合多肽及其用途
TW202241957A (zh) 抗ｐｄ－１抗體及其用途
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
HK40061359A (en) Antibodies targeting c5ar
JP2026514143A (ja) Ｏｘ４０ｌに結合する抗体及びその使用方法
WO2022012639A1 (zh) Pd-1抗原结合蛋白及其应用
CN118598997A (zh) 抗b7-h3抗体及其抗肿瘤应用
HK40061359B (zh) 靶向c5ar的抗体
Mårtensson Development of an Antigen-independent Affinity Assay to study the Binding of IgG to FcgammaR